| Primary |
| Product Used For Unknown Indication |
36.0% |
| Drug Use For Unknown Indication |
18.7% |
| Gastrooesophageal Reflux Disease |
5.3% |
| Prophylaxis Against Gastrointestinal Ulcer |
4.4% |
| Dyspepsia |
3.8% |
| Peptic Ulcer |
3.5% |
| Diabetes Mellitus |
3.2% |
| Prophylaxis |
3.2% |
| Gastritis |
2.9% |
| Hypertension |
2.9% |
| Antacid Therapy |
1.8% |
| Asthma |
1.8% |
| Blood Cholesterol |
1.8% |
| Lymphadenitis |
1.8% |
| Pulmonary Tuberculosis |
1.8% |
| Abdominal Pain Upper |
1.5% |
| Breast Cancer |
1.5% |
| Gastric Ulcer |
1.5% |
| Urticaria |
1.5% |
| Zygomycosis |
1.5% |
|
| Tubulointerstitial Nephritis |
13.0% |
| Electrocardiogram Qt Prolonged |
8.7% |
| Hepatitis |
7.6% |
| Liver Disorder |
6.5% |
| Thrombocytopenia |
6.5% |
| Urticaria |
6.5% |
| Nausea |
5.4% |
| Drug Interaction |
4.3% |
| Medication Error |
4.3% |
| Platelet Count Decreased |
4.3% |
| Acute Generalised Exanthematous Pustulosis |
3.3% |
| Completed Suicide |
3.3% |
| Delirium |
3.3% |
| Drug Ineffective |
3.3% |
| Eosinophilia |
3.3% |
| Hallucination |
3.3% |
| Poisoning |
3.3% |
| Renal Impairment |
3.3% |
| Troponin I Increased |
3.3% |
| Vitamin B12 Deficiency |
3.3% |
|
| Secondary |
| Product Used For Unknown Indication |
34.7% |
| Drug Use For Unknown Indication |
23.2% |
| Hypertension |
7.5% |
| Prophylaxis |
3.3% |
| Constipation |
3.2% |
| Gastritis |
3.0% |
| Gastric Ulcer |
2.8% |
| Sedation |
2.5% |
| Rheumatoid Arthritis |
2.5% |
| Pyrexia |
2.2% |
| Infection |
2.1% |
| Insomnia |
2.1% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.9% |
| Premedication |
1.6% |
| Antibiotic Therapy |
1.5% |
| Diabetes Mellitus |
1.4% |
| Cerebral Infarction |
1.3% |
| Gastrooesophageal Reflux Disease |
1.3% |
| Diuretic Therapy |
1.1% |
| Dyspepsia |
1.1% |
|
| Drug Rash With Eosinophilia And Systemic Symptoms |
12.8% |
| Toxic Epidermal Necrolysis |
12.3% |
| Liver Disorder |
9.5% |
| Interstitial Lung Disease |
6.4% |
| White Blood Cell Count Decreased |
6.1% |
| Death |
5.9% |
| Hepatic Function Abnormal |
5.0% |
| Thrombocytopenia |
5.0% |
| Pyrexia |
4.2% |
| Vomiting |
4.2% |
| Platelet Count Decreased |
3.6% |
| Stevens-johnson Syndrome |
3.6% |
| Delirium |
2.8% |
| Nausea |
2.8% |
| Rash |
2.8% |
| Toxicity To Various Agents |
2.8% |
| Urticaria |
2.8% |
| Poisoning |
2.5% |
| Venous Thrombosis Limb |
2.5% |
| Hepatitis |
2.2% |
|
| Concomitant |
| Product Used For Unknown Indication |
25.4% |
| Drug Use For Unknown Indication |
16.2% |
| Prophylaxis |
13.0% |
| Rheumatoid Arthritis |
7.4% |
| Hypertension |
6.5% |
| Pain |
3.2% |
| Infection Prophylaxis |
2.8% |
| Constipation |
2.7% |
| Multiple Myeloma |
2.7% |
| Premedication |
2.4% |
| Gastritis |
2.3% |
| Hepatitis C |
2.2% |
| Diabetes Mellitus |
2.1% |
| Insomnia |
2.0% |
| Gastrooesophageal Reflux Disease |
1.7% |
| Hiv Infection |
1.7% |
| Depression |
1.5% |
| Osteoporosis |
1.4% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.4% |
| Nausea |
1.4% |
|
| White Blood Cell Count Decreased |
11.9% |
| Vomiting |
11.5% |
| Pyrexia |
7.8% |
| Pneumonia |
6.1% |
| Sepsis |
5.5% |
| Interstitial Lung Disease |
5.3% |
| Thrombocytopenia |
5.2% |
| Rash |
5.0% |
| Weight Decreased |
4.7% |
| Death |
4.1% |
| Weight Increased |
4.0% |
| White Blood Cell Count Increased |
3.8% |
| Platelet Count Decreased |
3.6% |
| Renal Impairment |
3.6% |
| Nausea |
3.3% |
| Respiratory Failure |
3.1% |
| Liver Disorder |
2.9% |
| Renal Failure |
2.9% |
| Urinary Tract Infection |
2.9% |
| Hepatic Function Abnormal |
2.7% |
|
| Interacting |
| Zygomycosis |
18.6% |
| Product Used For Unknown Indication |
14.0% |
| Convulsion Prophylaxis |
9.3% |
| Prophylaxis |
9.3% |
| Delirium |
4.7% |
| Drug Use For Unknown Indication |
4.7% |
| Hypersensitivity |
4.7% |
| Oesophagitis |
4.7% |
| Pneumonia |
4.7% |
| Blood Cholesterol Increased |
2.3% |
| Blood Pressure High |
2.3% |
| C-reactive Protein Increased |
2.3% |
| Constipation |
2.3% |
| Convulsion |
2.3% |
| Gastritis |
2.3% |
| Hyperchlorhydria |
2.3% |
| Hypercholesterolaemia |
2.3% |
| Pyrexia |
2.3% |
| Restlessness |
2.3% |
| Rhizopus Infection |
2.3% |
|
| Drug Interaction |
18.8% |
| Vomiting |
18.8% |
| Drug Level Decreased |
6.3% |
| Electrocardiogram Qt Prolonged |
6.3% |
| Flushing |
6.3% |
| Hyperchlorhydria |
6.3% |
| Liver Disorder |
6.3% |
| Malabsorption |
6.3% |
| Prescribed Overdose |
6.3% |
| Pulmonary Eosinophilia |
6.3% |
| Pulmonary Haemosiderosis |
6.3% |
| Speech Disorder |
6.3% |
|
